By Lilian Massihi, MD, Board-Certified Family Medicine, Advanced BHRT Certification
You noticed it in a photograph, or in the shower drain, or the morning the elastic went around three times instead of two. There was no bald patch and no single day it happened. There is just less hair than you had, and more scalp showing along the part than you remember.
You brought it up and heard one of two answers. It is genetic. Or it is your age. Both are the kind of answer that closes a conversation instead of opening one.
So you went to the aisle instead. The thickening shampoo, the scalp serum, the collagen powder, the biotin gummies with four thousand reviews. Some of it seemed to help for a few weeks. None of it changed what you see in the mirror.
Here is what the aisle cannot tell you. Thinning hair in the menopause transition is not a scalp condition that happened to turn up in your forties. It is a follicle responding to a hormonal change that is happening everywhere in your body at once, and a product applied to the scalp is working several steps downstream of the thing that actually changed. Worse, one of the supplements sold hardest for hair can distort the very blood tests a physician would use to find out what changed.
What is actually happening to the follicle
The pattern has a name and a mechanism. In its review of treatments for female pattern hair loss, the Cochrane Collaboration, the international group that grades medical evidence for a living, describes it as a progressive shortening of the hair’s growth phase with each successive cycle, along with progressive miniaturisation of the follicle: thick, long terminal hairs are gradually replaced by soft, fine, short ones.
That is why it reads as thinning rather than balding. You are not losing the follicles so much as demoting them. Each cycle the follicle keeps its place and produces a finer, shorter hair than it did the time before. The number of hairs on your head can change very little while the mass of your ponytail drops by half, which is exactly why the ponytail is a better report than any count, and why a photograph from four years ago is better evidence than a hairbrush.
It is also why it gets missed. The front hairline may be preserved or may not be, so it rarely looks like the male version anyone is watching for. And this is not a rare problem waiting at the edge of medicine: a comprehensive review in Dermatologic Therapy, a peer-reviewed dermatology journal, records female pattern hair loss as the most common cause of hair loss in women, rising in incidence with age, with an origin that is still not fully settled and several factors known to influence when it starts.
Why it starts now
The timing is not a coincidence, and it is the part that gets left out.
Across the transition, estradiol falls. The androgen side of the ledger falls more slowly, so the ratio between them shifts, and follicles that are inherited sensitive to androgen respond to that shift by miniaturising. A review in the European Journal of Dermatology, the journal of the European Dermatology Forum, puts it plainly: the reduction in ovarian hormones and the rise in relative androgen effect after the final period can show up as hair and skin disorders, and those disorders receive very little attention compared with the other symptoms of menopause, while the cosmetic industry markets to this same group of women heavily and they spend accordingly.
Read that twice, because it explains your last four years. The attention went to the aisle. It did not go to the mechanism.
It is the same reason the skin of the transition changes at the same time, which is a separate article and a recognisable story of its own. Hair and skin are both estrogen-responsive tissue. They tend to report the change together.
“It is genetic” and “it is hormonal” are the same sentence
The answer you were given is not wrong. It is half an answer.
Which of your follicles are sensitive to androgen is inherited, and nobody can change that. What changed in your forties is not the inheritance. It is the hormonal environment those follicles are sitting in. Genetics loaded the pattern years ago; the transition is what pulled it forward into view.
That distinction matters for one practical reason. The inherited half cannot be measured and cannot be moved. The hormonal half can be measured. Being told “it is genetic” and sent home retires the only half of the problem that was available to you.
Three things that are not the transition, and get missed anyway
Shedding is not thinning. They are different complaints with different causes, and a physician needs to know which one you are describing. Losing noticeably more hair than usual, in handfuls, starting fairly suddenly and often a couple of months after an illness, a surgery, a sharp weight loss or a severe stressor, behaves differently from the slow miniaturisation above. The two can run at the same time, and when they do, the sudden one is usually the one worth chasing first because it is more often reversible.
Thyroid. Hair is one of the first places an undertreated thyroid declares itself, and it is also the most common finding that gets waved off because a single number came back inside its range. If you have been told your thyroid is fine while your body disagrees, that question deserves reopening before anything is blamed on the transition.
Iron. Low iron stores have been linked to increased hair shedding in women, though the clearest case-control work is in women of childbearing age rather than women past their final period, so it should be read as a reason to look rather than a reason to assume. And here the age matters more than the hair does. A review in the Journal of the American Academy of Dermatology, the peer-reviewed journal of the American Academy of Dermatology, notes that in postmenopausal women the most common causes of iron deficiency anaemia are gastrointestinal blood loss and malabsorption, and that the cause of the deficiency has to be identified rather than simply corrected. A woman past menopause with low iron does not need a gummy. She needs to know why it is low.
What the evidence actually supports, and what it does not
This is where a post like this usually turns into a product list. Instead, here is what the trials say, including the parts that are inconvenient.
The Cochrane review above pooled 47 randomised trials covering 5,290 women. Only five of those 47 were rated at low risk of bias; 26 were unclear and 16 were high. Funding was reported in 26 of the 47, mainly from pharmaceutical companies. So the literature behind this entire category is thinner and more conflicted than the confidence of the marketing around it.
Within that literature:
- Topical minoxidil has the most consistent support. Pooled across six studies, women using it reported at least moderate regrowth roughly twice as often as women on placebo (risk ratio 1.93, 95% confidence interval 1.51 to 2.47, graded moderate quality), and across eight studies total hair count rose by about 13 hairs per square centimetre over placebo (confidence interval 10.92 to 15.44, graded low quality). It is sold without a prescription. It is also worth saying what 13 hairs per square centimetre is: a real, measurable change, and a modest one. Not a transformation.
- The 5 percent strength was not better than the 2 percent on most outcomes in four studies covering just over a thousand women.
- Finasteride was no more effective than placebo in the trials included here, on low quality evidence.
- Low-level laser combs and caps did not beat a sham device in the judgment of the women using them, across two studies and 141 participants, although hair counts did rise in both. The devices are sold on the hair-count half of that sentence and not the other half.
- Several of the most widely prescribed options have not been properly tested. Cochrane’s own closing recommendation names spironolactone, other doses of finasteride, dutasteride, cyproterone acetate and laser therapy as treatments in common use that still need randomised trials. That is a statement about the evidence, not about whether any one of them belongs in your chart, which is a prescribing decision for a physician who can see your whole history.
And the question you are actually here for. Does hormone therapy regrow hair? A review in Dermatology, a peer-reviewed dermatology journal, written for clinicians treating hair, examined exactly that and concluded that the data are sparse and inconsistent on what estrogen-containing and progesterone-containing therapies do to hair.
So no. We are not going to tell you that hormone therapy will bring your hair back, because the trials do not support that claim and this practice does not make claims the trials do not support. The honest version is narrower and still worth something: the hormonal shift is part of why this started, it is measurable, and it has consequences well beyond your hair that are worth evaluating on their own merits. If anyone tells you hormone therapy is a hair treatment, ask them which trial they are quoting.
The supplement aisle, and the part nobody mentions
Biotin is in almost every hair product sold, and the reason is real: biotin deficiency genuinely does cause hair loss. The leap is what happens next.
The biotin fact sheet from the Office of Dietary Supplements at the National Institutes of Health states that biotin deficiency is rare, and that the claims made for supplementation are supported, at best, by only a few case reports and small studies. A systematic review in Skin Appendage Disorders went looking for the evidence directly and found 18 reported cases of biotin used for hair and nail changes. Every single patient in those cases had an underlying condition causing poor growth. The evidence is about correcting a deficiency, not about adding biotin to a woman who already has enough of it.
Now the part that matters most in a practice that runs labs, and that the bottle will never tell you.
High intakes of biotin interfere with laboratory assays built on biotin-streptavidin technology, and that technology sits underneath many of the tests used to measure hormones, thyroid hormone among them, as well as vitamin D. The interference does not make the result unreadable. It makes it wrong in a way that still looks perfectly plausible: reassuring when it should not be, or alarming when it should not be. The same fact sheet documents it, and the Food and Drug Administration has gone as far as publicly naming the troponin tests that have not addressed the problem, after continuing to receive reports of falsely low results. One patient taking a high dose of supplemental biotin died following a troponin test that read low because of it.
Follow that through to your own situation. A woman’s hair starts thinning. She buys a high-dose biotin supplement. She finally gets her thyroid checked to find out why her hair is thinning, and the supplement she bought for her hair can skew the result that would have explained it. That is not a hypothetical. It is the reason we ask what you are swallowing before we draw a single tube.
What is worth measuring
There is a short, honest list: thyroid function, iron studies including ferritin, and the hormonal picture of the transition itself, read against your history rather than against a symptom.
Which parts of that list apply to you is a physician’s decision made with your chart open, which is why you will not find a fixed panel or a testing schedule published here. There is not one. A woman who is three years past her last period, shedding in handfuls since a surgery, with a family history of thyroid disease, needs a different first move than a woman whose part has been widening slowly since she was forty-four.
And one more thing a hormone optimization practice should say out loud. Not all hair loss is hormonal. Hair loss that leaves a scarred or smooth patch, that comes with scalp pain, scaling or redness, that arrives suddenly in a defined circle, or that simply does not fit a pattern, is a dermatologist’s question and sometimes an urgent one. A practice that tells you every kind of hair loss runs through hormones is selling you something. The useful version of physician-led care is knowing which part of this is ours and saying so about the rest.
What to do with this
Three things, in this order, and none of them involve a review count.
First, work out whether you are describing shedding or thinning, because that single distinction redirects the whole evaluation. Second, write down everything you are taking, gummies and powders included, and hand that list over before any blood is drawn. Third, ask for the hormonal and the non-hormonal contributors to be looked at together rather than ruled out one purchase at a time.
That third step is the one the aisle cannot sell you, and it is bigger than your hair. Thinning is one line in a much longer report on what the transition is doing to bone, metabolism, sleep and mood at the same time, which is why it belongs inside a physician-led evaluation of the menopause transition rather than in a separate appointment about your scalp.
None of that is a promise about your hair. What it buys you is an answer with a mechanism in it, and a decision based on your own numbers instead of someone else’s testimonial. After four years in the aisle, that is not a small upgrade.
Frequently Asked Questions
Will my hair grow back?
Honestly, it depends on which process you have. Sudden diffuse shedding triggered by an illness, a surgery, a sharp weight loss or a severe stressor is often reversible once the trigger is addressed. The slow miniaturisation of pattern hair loss behaves differently: the realistic goal there is holding ground and improving density, not restoring the hair you had at thirty. Any practice that promises you that second outcome is making a claim the research does not support.
I am five years past my last period. Is it too late to bother looking?
No, and for two reasons. A reversible contributor like thyroid disease or iron deficiency does not expire, and it is worth finding at any point. And in a woman past menopause, low iron is itself a finding that needs a cause rather than a supplement, which is a reason to look that has nothing to do with your hair.
Should I stop taking biotin?
That is a conversation to have with your physician rather than a decision to make from an article. What matters most is that whoever orders your labs knows you are taking it, and how much, because the interference with thyroid and other hormone assays is well documented. Telling the person reading your results is not optional.
Does hormone therapy treat hair loss?
The published data on what estrogen-containing and progesterone-containing therapies do to hair are sparse and inconsistent, so it is not an established hair treatment and we do not present it as one. The hormonal shift of the transition is part of why thinning begins, and it is worth evaluating for its own reasons across bone, metabolism, sleep and symptoms. Hair is not the reason to start it.
How do I know whether this is my thyroid or the transition?
You do not, from the outside, and neither does anyone selling you a product. They can also both be true at once. That is what the measuring is for, and it is why the thyroid question gets asked first when the history points that way, rather than after a year of serums.
Is topical minoxidil worth trying?
It carries the most consistent trial evidence of anything in this category, which is a genuine point in its favour, and the size of the effect in those trials was modest. It also does nothing about a thyroid problem or an iron problem, so starting there before anyone has looked for a cause risks treating the surface of something that had an explanation. Raise it with a physician who knows what else is going on.
AllureMD is a physician-led hormone optimization practice in Madison, Mississippi. Thinning hair is one of the changes of this transition most often answered with a product instead of an evaluation, which is why the measurable contributors are worth separating from the inherited ones. Lilian Massihi, MD evaluates each patient’s complete hormonal picture before making any recommendation. To schedule your consultation, book a complimentary discovery call.
About the Author
Lilian Massihi, MD is a board-certified family medicine physician and hormone optimization specialist who completed her undergraduate education at UCLA, earned her medical degree at the University of Poznań, and finished her residency at the University of Mississippi Medical Center. For more than five years, she practiced as a hospitalist, treating patients in the late stages of cardiovascular disease, cognitive decline, and severe osteoporosis. She kept asking the same question: what would have been different if someone had intervened sooner? That question led her to bioidentical hormone therapy, where a rigorous review of the evidence changed the direction of her career. She founded AllureMD in Madison, Mississippi to practice the kind of medicine she had come to believe in: treating the entire hormonal system, titrating to how patients actually feel, with a physician leading every decision.